Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Haemolytic uraemic syndrome
- Focus Therapeutic Use
- Acronyms ECULISHU
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Status changed from recruiting to completed.
- 25 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.